0000000000809882

AUTHOR

Günter Niegisch

showing 3 related works from this author

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct

Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 g…

2011

Genotyping N-acetyltransferase 2 (NAT2) is of high relevance for individualized dosing of antituberculosis drugs and bladder cancer epidemiology. In this study we compared a recently published tagging single nucleotide polymorphism (SNP) (rs1495741) to the conventional 7-SNP genotype (G191A, C282T, T341C, C481T, G590A, A803G and G857A haplotype pairs) and systematically analysed if novel SNP combinations outperform the latter. For this purpose, we studied 3177 individuals by PCR and phenotyped 344 individuals by the caffeine test. Although the tagSNP and the 7-SNP genotype showed a high degree of correlation (R=0.933, P0.0001) the 7-SNP genotype nevertheless outperformed the tagging SNP wit…

MaleLinkage disequilibriumGenotypeGenotyping TechniquesArylamine N-AcetyltransferaseMedizinSingle-nucleotide polymorphismComputational biologyBiologyPolymorphism Single NucleotideSensitivity and SpecificityLinkage DisequilibriumCaffeineGenotypeEthnicityGeneticsmedicineHumansSNPGeneral Pharmacology Toxicology and PharmaceuticsMolecular BiologyGenotyping TechniquesGenotypingGenetics (clinical)Bladder cancerHaplotypeAcetylationmedicine.diseasePhenotypeHaplotypesCase-Control StudiesMolecular MedicineFemale
researchProduct

Activation of classical protein kinase C reduces the expression of human cationic amino acid transporter 3 (hCAT-3) in the plasma membrane

2005

We have previously shown that activation of PKC (protein kinase C) results in internalization of hCAT-1 [human CAT-1 (cationic amino acid transporter 1)] and a decrease in arginine transport [Rotmann, Strand, Martiné and Closs (2004) J. Biol. Chem. 279, 54185–54192]. However, others found increased transport rates for arginine in response to PKC activation, suggesting a differential effect of PKC on different CAT isoforms. Therefore we investigated the effect of PKC on hCAT-3, an isoform expressed in thymus, brain, ovary, uterus and mammary gland. In Xenopus laevis oocytes and human U373MG glioblastoma cells, hCAT-3-mediated L-arginine transport was significantly reduced upon treatment with…

TeratocarcinomaArginineXenopusDown-RegulationArginineBiochemistryEnzyme activatorAntibody SpecificityCell Line TumorTumor Cells CulturedAnimalsHumansMolecular BiologyProtein Kinase CProtein kinase CCationic Amino Acid Transporter 1Arginine transportbiologyActivator (genetics)Cell MembraneBiological TransportCell BiologyFusion proteinEnzyme ActivationBiochemistryTetradecanoylphorbol AcetateOocytesbiology.proteinTetradecanoylphorbol AcetateCATIONIC AMINO ACID TRANSPORTER 3GlioblastomaResearch ArticleBiochemical Journal
researchProduct